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Introduction. Concern about the potential detrimental side-effects of b-blockade on pulmonary function often dissuades
against their perioperative use in patients undergoing major arterial surgery (especially in those with chronic obstructive
pulmonary disease (COPD)). In this study we aimed to establish prospectively the clinical relevance of these concerns.
Methods. After ethics committee approval and individual informed consent, the pulmonary function of twenty patients
(mean age 68.7 years (range 43e82), 11 males) scheduled to undergo non-emergency major vascular surgery was studied
by recording symptoms and spirometry before and after institution of effective b-blockade. Fifteen patients (75%) had
significant smoking histories (mean pack years/patient¼ 50), while 12 (60%) had COPD.
Results. All patients tolerated effective b-blockade satisfactorily without developing either subjective deterioration in symp-
toms or significant change on spirometry. The mean change in FEV1 following adequate b-blockade was 0.05 0.24 liters
(95% CI 0.06 to þ1.61), p¼ 0.35, giving a mean percentage change of 3.18% 11.66 (95% CI 2.26 to 8.62).
Conclusions. Previously held concerns about worsening pulmonary function through the short-term use of b-blockers
should not dissuade their perioperative usage in patients with peripheral vascular disease. Furthermore, the accuracy of
pulmonary function tests in preoperative assessment and risk stratification also appears unaffected by this therapy.
Keywords: Perioperative b-blockade; Peripheral arterial surgery; Peripheral vascular disease; Perioperative cardiac risk.Introduction
Consideration of perioperative b-blockade is advo-
cated as being an integral part of routine patient prep-
aration for major vascular surgery, in particular for
those at high risk of serious cardiac morbidity who
require peripheral arterial reconstruction for athero-
sclerotic disease.1e3 However, there is an apparent
reluctance among physicians to prescribe these medi-
cations in patients with chronic obstructive pulmo-
nary disease (COPD)4e7 perhaps because the harm:
benefit relative risk ratio of this practice for individuals
has yet to be fully elucidated. Furthermore, some
concerns may exist over the effects such therapy
may have on preoperative risk stratification as pul-
monary function testing plays an important role in
determining patient fitness for general anaesthesia.
While several other studies have attempted to address
historical concerns regarding the use of this therapy
*Corresponding author. Ms MC Barry, FRCSI, Consultant Vascular
Surgeon, St. Vincent’s University Hospital, Elm Park, Dublin 4,
Ireland.
E-mail address: mary.barry@st-vincents.ie1078–5884/000305+ 04 $35.00/0  2006 Elsevier Ltd. All rights resein patients with respiratory impairment, none, to
our knowledge, have focused on the effects of b-
blockade on lung function before surgery in the pa-
tients likely to gain the most from this intervention.
The purpose of this prospective, cohort study was
to examine the effects of effective b-blockade on lung
function in patients being optimized for major vascular
surgery.
Patients and Methods
After obtaining local ethics committee approval and
fully informed individual patient consent, consecutive
patients admitted electively for major peripheral arte-
rial surgery were considered for this study. All under-
went detailed assessment of their degree of subjective
dyspnoea as well as pulmonary function testing (PFT)
both before and after the introduction of effective car-
dioselective b-blockade. PFT assessment included full
spirometry and reversibility studies (FEV1 response
to inhaled b-agonist medication). The baseline mea-
surement for each patient therefore acted as the con-
trol reading for that individual. Repeat assessmentrved.
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their operation (to exclude the confounding effects
of postoperative atelectasis). No patient was already
using b blocker medication and those with a definite
contraindication to b-blockade (i.e. medication allergy,
brittle diabetes, heart block and systemic hypotension)
were not considered for the study.
Oral metoprolol was used to induce b-blockade in
all patients, the dose of which was titrated to ensure
an effective level of b-blockade (manifest clinically
as a resting pulse rate of 65 beats per minute recorded
on three separate occasions). Adequacy of b-blockade
in those patients undergoing surgery was further
assessed by determining the need for supplemental
intravenous b-blocker therapy intraoperatively to
maintain heart rate during surgery below 65 beats/
minute. Pulmonary function testing was carried out
according to established guidelines.8 The Forced Expi-
ratory Volume in One Second (FEV1), Forced Vital
Capacity (FVC) and the degree of reversibility present
were measured utilising a calibrated Jaeger MS-PFTsys-
tem which records FEV1 with an accuracy of 0.2 L/s
(manufacturer’s data) and has a coefficient of varia-
bility of 3.3%.9 The best of a minimum of three
technically acceptable efforts was reported while an
appropriate comment was recorded to indicate non-
reproducible tests. A significant degree of reversibility
was judged to be present if the FEV1 or FVC increased
by 12% or more after inhalation of salbutamol (400 mg).
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) Classification was used to determine
the presence and severity of COPD in the study
group.10
Power calculation and statistical analyses: Assum-
ing a mean FEV1 of 2 L/sec, a sample size of 20
patients was calculated as being necessary to detect
a reduction of 200 ml/sec with a significance of
a¼ 0.05 to a power of 90% when using paired samples
t-Test for repeated observations. Pearson correlative
analysis was also used to demonstrate similarity
between pre- and post-b-blockade scores. All data were
recorded onMicrosoft Excel datasheets and analyzed
using Analyse-it software (Analyse-it Software Ltd,
Leeds, England).
Results
The mean age of the twenty patients included in this
study was 69.9 years (range 82e43 years). Eleven pa-
tients were male. Fourteen patients were admitted for
operative management of peripheral vascular disease
(eight had disabling claudication, six had rest pain or
ulceration). Six patients were admitted for repair ofEur J Vasc Endovasc Surg Vol 32, September 2006aneurysmal disease (five had abdominal aortic aneu-
rysms while one had an internal iliac artery aneu-
rysm). Fifteen patients had significant smoking
histories having a mean pack-year history of fifty.
Three patients were continuing smokers. Six patients
were known to have diabetes mellitus (one on insu-
lin). No patient was, at the time of the study, receiving
oral steroids.
After baseline measurement of pulmonary func-
tion, oral metoprolol therapy was instigated and
titrated to a resting heart rate of <65 bpm. The mean
duration of b-blockade prior to second recordings
was 5.1 days (range 3 to 15 days). Seventeen patients
were effectively b-blocked on a dose of 25 mg of me-
toprolol twice daily, while two patients required
50 mg twice daily. One patient required only 25 mg
once daily. Only one patient required supplemental
intra-operative intravenous b-blockade. No patient
suffered an adverse reaction to their treatment (either
pre- or intraoperatively) nor did any report a worsen-
ing of lung symptomatology.
All twenty patients had pre- and post-b-blocker
spirometry. Six patients were found to have mild
COPD on initial spirometry while another six had
moderate disease at the time of their admission. Thir-
teen individuals also had airway reversibility in re-
sponse to salbutamol measured before and after
their b-blockade (the remaining patients were unable
to satisfactorily perform this part of the study in a con-
sistent manner or had received beta agonist inhalers
for therapeutic reasons on the day of the inves-
tigation). One patient had significant reversibility
detected before the institution of effective b-
antagonism although this individual did not have
COPD.
The absolute change in FEV1 in fifteen patients was
less than 0.2 L/s while no patient had a decrease in
FEV1 greater than 0.3 L/s. The mean standard devi-
ation pre-b-blockade FEV1 was 1.92 0.67 litres (95%
CI 1.6 to 2.23) while the FEV1 post-b-blockade was
1.97 0.71 liters (95% CI 1.6 to 2.3). Therefore, the
mean change in FEV1 following adequate b-blockade
was þ0.05 0.24 liters (95% CI 0.06 to þ1.61)
(p¼ 0.35) while the mean percentage change was
3.18% 11.66 (95% CI 2.26 to 8.62). The correlation
between the before and after values of the patients
is shown in Fig. 1 (Pearson r statistic is 0.94 (95% CI
0.86 to 0.98)). There was no significant difference in
change of FEV1 between those with either mild or
moderate COPD (see Table 1). Although improvement
in postoperative convalescence was not the formal in-
tent of this study, no patient suffered significant respi-
ratory or cardiac complication either during or after
their surgery.
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Peripheral vascular disease is often associated with
significant pulmonary and coronary co-morbidity
due to the presence of shared risk factors, especially
cigarette smoking. As patients with these diseases
are at relatively high risk of peri- and postoperative
complications such as myocardial ischaemia and re-
spiratory failure, careful preoperative assessment
and optimization is crucial to the provision of success-
ful surgical therapy. The benefits of perioperative b-
blockade in patients undergoing major non-cardiac
vascular surgery who are at high risk of serious car-
diac complications perioperatively are now clearly
established as large cohort studies have definitively
shown a marked reduction in the incidence of both myo-
cardial ischaemia and death in both the short and
medium terms.11e13 Amongst others, Poldermans et al.
has demonstrated a 91% reduction in relative risk of
perioperative cardiac morbidity and mortality in such
a patient group.13
However, despite such compelling evidence of ben-
efit, b-blockade in the perioperative period remains an























Fig. 1. Graph demonstrating values of FEV1 before and after
adequate establishment of b-blockade.for those with COPD and may be because traditional
teaching cautions that b-blockers may precipitate
bronchospasm in this group (although cardioselective
b-antagonists are routinely advocated in order to min-
imise the incidence of adverse effects outside the car-
diovascular system, no such agent has proven to be
entirely b1 specific in its effects). Furthermore, it has
been unclear how the perioperative institution of
b-blockade may affect the categorisation of patient’s
symptom severity, operative risk and postoperative
outcome as pulmonary function testing are a standard
part of selection and assessment for operative inter-
vention. Spirometry is routinely used in order to
guide preoperative risk stratification16,17 as well as
to aid in the selection of the most appropriate man-
agement strategy (i.e. whether surgery or medical
management is appropriate as well as whether open
or endovascular techniques are preferable). Further-
more by demonstrating bronchial reactivity and the
degree of reversibility induced by inhaled b2-agonists,
preoperative pulmonary function testing facilitates
patient optimisation prior to surgery. A significant
reduction in these measurements mediated by phar-
macotherapy could impact markedly on clinical deci-
sions and care.
There is therefore uncertainty over how best clini-
cal practice should be adjusted for patients with
peripheral vascular disease requiring operation who
have, or likely to have, COPD. These concerns seem
to persist despite one recent study showing metopro-
lol to be safe in patients with concomitant COPD and
coronary artery disease18 while both systematic
reviews (including two Cochrane Reviews)19e21 as
well as a recent large retrospective study22 have
shown that these medications are well tolerated in
the majority of patients with COPD (including those
with mildmoderate reversible airways disease).
This study demonstrates no significant change in
FEV1 following the institution and appropriate titra-
tion of a b1 selective blocker in a population of vascu-
lar patients (mostly without reversible airway disease)
being prepared for major arterial reconstructive pro-
cedures. Metoprolol was used because of its short
half life and therefore ease of titration to effective
levels as well as its b1 selectivity. The timing of the
introduction of the medication preoperatively andTable 1. FEV1 before and after institution of effective b-blockade by degree of COPD present
Degree of COPD n FEV1: Mean value S.D. (L/sec)
Before After Change % Change
None 8 2.16 0.43 2.19 0.39 0.03 0.18 2.10 9.29
Mild 6 1.93 0.90 1.97 0.84 0.04 0.11 4.20 7.92
Moderate 6 1.57 0.65 1.66 0.91 0.09 0.39 3.50 18.08Eur J Vasc Endovasc Surg Vol 32, September 2006
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with published recommendations. The use of a clinical
measure of ‘‘adequate’’ b-blockade (i.e. resting heart
rate) seems arbitrary, but is consistent with the meth-
odology and recommendations of the multi-centre
studies that proved the beneficial effects of the
medication.
The patients studied in this report were selected by
no other means then by their requirement for vascular
surgery and seem typical of the usual demographic in
that they tended to be elderly and many had signifi-
cant smoking histories. The degree of concomitant
COPD was to be expected in this group- although
no patient had severe COPD, many patients in this
category are excluded from elective surgical proce-
dures due to the degree of their pulmonary co-
morbidity. Although the number of patients studied
may seem small, it is consistent with and, indeed, ex-
ceeds many previously published studies designed to
examine the effects of b-blockade on lung function in
different clinical settings.23
In summary, this study provides further reassur-
ance for clinicians trying to optimize patient outcome
after vascular operation and supports the prescribing
of b-blockers for outpatients prior to their planned
admission for operation.
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